ライフサイエンスコーパス: tumor vaccine

1 P and HMGB1, and functioned effectively as a tumor vaccine.

2 eveloped a novel GM-CSF-secreting pancreatic tumor vaccine.

3 opyranosyl lipid A (GLA), using a whole-cell tumor vaccine.

4 pilot clinical trial using Ag-pulsed DC as a tumor vaccine.

5 cells pulsed with recombinant mouse PAP as a tumor vaccine.

6 inant virus to serve as a safe and effective tumor vaccine.

7 ion therapy's ability to generate an in situ tumor vaccine.

8 ability of radiation to generate an in situ tumor vaccine.

9 roved formulation of chaperone protein-based tumor vaccine.

10 94 (GRP94/gp96) has shown great promise as a tumor vaccine.

11 h the murine anti-idiotype antibody 3H1 as a tumor vaccine.

12 linical trial designs for the development of tumor vaccines.

13 e important implications for the crafting of tumor vaccines.

14 TCR complex are significantly more potent as tumor vaccines.

15 compatibility antigens (mHAgs) in whole-cell tumor vaccines.

16 od to enhance the activity of nonimmunogenic tumor vaccines.

17 asis for new generations of antigen-specific tumor vaccines.

18 may provide a new avenue for development of tumor vaccines.

19 act or tumor RNA, and cytokine gene-modified tumor vaccines.

20 d suggests it may enhance the development of tumor vaccines.

21 roblasts as vehicles to deliver cytokines in tumor vaccines.

22 orspecific CTLs may lead to epitope-specific tumor vaccines.

23 th metastatic melanoma who were administered tumor vaccines.

24 HLA is very important for the development of tumor vaccines.

25 -targeted therapies, radioimmunotherapy, and tumor vaccines.

26 A-II molecular peptides for the synthesis of tumor vaccines.

27 ancer cells and examined their properties as tumor vaccines.

28 tive strategy for increasing the efficacy of tumor vaccines.

29 or the optimization of antigen-specific anti-tumor vaccines.

30 vel agents such as targeted therapeutics and tumor vaccines.

31 g the possibility of generating in situ anti-tumor vaccines.

32 an improve the clinical efficacy of DC-based tumor vaccines.

33 n targeted for the development of colorectal tumor vaccines.

34 ation, therefore acting as potential in situ tumor vaccines.

35 en-presenting cells with a potential role in tumor vaccines.

36 age tumors, and may help improve therapeutic tumor vaccines.

37 fort to increase the therapeutic efficacy of tumor vaccines.

38 herapy with agents such as interleukin-2 and tumor vaccines.

39 tilized in the design of novel peptide-based tumor vaccines.

40 gests a novel approach to the development of tumor vaccines.

41 uggest that using cell-associated dsRNA as a tumor vaccine adjuvant may be a suitable strategy for en

42 We conclude that tumor vaccines administered after allogeneic BMT can aug

43 gate recombinant Listeria monocytogenes as a tumor vaccine against s.c. and intracerebral challenges

44 neic, HER2-positive, GM-CSF-secreting breast tumor vaccine alone or with CY and DOX is safe and induc

45 In addition, tumor vaccines alone have a limited potential for the tr

46 col by comparing tumors treated with in situ tumor vaccines, analyzing both fresh and cryopreserved t

47 In addition, a mesothelin tumor vaccine and a mesothelin- chimeric antigen recepto

48 ical quality of a recombinant poxvirus-based tumor vaccine and that the use of promoters capable of d

49 efore likely to serve as a strategy for both tumor vaccines and adoptive immunotherapy of cancer.

50 Tumor vaccines and cellular immunotherapies could synerg

51 Tumor vaccines and cellular immunotherapies enhanced OS

52 re are major differences between therapeutic tumor vaccines and chemotherapeutic agents that have imp

53 be generally used to improve the efficacy of tumor vaccines and immunotherapies.

54 ons in the induction of cellular immunity by tumor vaccines and may have important implications for f

55 immunomodulator in combination with in situ tumor vaccines and need to analyze radioactive samples f

56 relevant to the clinical evaluation of human tumor vaccines and suggests that cell-mediated cytolytic

57 vileged" CNS would pose to cytokine-assisted tumor vaccines and what cytokines would be most efficaci

58 apies including second-generation retinoids, tumor vaccines, and new modes of drug delivery with impr

59 In the ex vivo tumor vaccine approach, B16 melanoma cells, transduced i

60 Allogeneic GM-CSF-secreting tumor vaccines are safe in patients with pancreatic aden

61 c, phase I/II trials support the notion that tumor vaccines are safe.

62 an parental tumor, and CIITA expression in a tumor vaccine assay lacked efficacy.

63 sed for preclinical evaluations of viral and tumor vaccines based on alpha-Gal epitopes, human-specif

64 ntigens are chosen as primary candidates for tumor vaccine because of their expression on multiple li

65 e have developed an in vivo HSP-suicide gene tumor vaccine by generating a recombinant replication-de

66 to the tumor can convert it into an in situ tumor vaccine by inducing release of antigens during can

67 We generated a cellular tumor vaccine by pulsing dendritic cells with enriched m

68 esentation and for developing more effective tumor vaccines by silencing the critical brake in antige

69 Tumor vaccines can be used to induce immunologically spe

70 colony-stimulating factor (GM-CSF)-secreting tumor vaccines can cure established tumors in the mouse,

71 Although tumor vaccines can increase the number of tumor-specific

72 al studies have demonstrated that autologous tumor vaccines can induce relatively specific tumor-reac

73 r histocompatibility antigens (mHAgs) on the tumor vaccine cells.

74 ndritic cells and macrophages among prostate tumor vaccine cells.

75 colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic syner

76 en seen in colon cancer patients receiving a tumor vaccine comprised of this altered peptide.

77 IL-2- and CD40L-expressing recipient-derived tumor vaccine consisting of leukemic blasts admixed with

78 Cell-based tumor vaccines, consisting of MHC class I+ tumor cells e

79 Lymph nodes (LN) draining both D5 and D5-Kd tumor vaccines contained increased numbers of cells with

80 pressing Line 1 cells served as an effective tumor vaccine, demonstrating that CD86 is effective in i

81 nd enhancement of this process is a focus of tumor vaccine design.

82 ansplantation, but also for autoimmunity and tumor vaccine design.

83 peutic CD8(+) T cells by a GM-CSF-transduced tumor vaccine did not require CD40 and CD40L interaction

84 ils to generate therapeutic T cells from the tumor vaccine-draining lymph nodes (TVDLN) in our adopti

85 or-specific T cells preferentially expand in tumor vaccine-draining lymph nodes after a melanoma vacc

86 hat priming of therapeutic CD8(+) T cells in tumor vaccine-draining lymph nodes of mice vaccinated wi

87 generated D5-specific effector T cells from tumor vaccine-draining lymph nodes of wild type (wt), pe

88 resensitized CD25-depleted T cells increased tumor vaccine efficacy.

89 s through PIR-B-NOTCH signaling and enhances tumor vaccine efficacy.

90 e responses, and LATS1/2 deficiency enhances tumor vaccine efficacy.

91 fic mAb with a neu-targeted GM-CSF-secreting tumor vaccine enhanced induction of neu-specific CD8(+)

92 pproach gaining increasing popularity in the tumor vaccine field is to immunize cancer patients with

93 recognized by T cells has revolutionized the tumor vaccine field.

94 modified tumor cells can be used as a potent tumor vaccine for both autologous and HLA class I-matche

95 op an improved formulation of HSP70.PC-based tumor vaccine for patient use, we extracted HSP70.PC-F f

96 encoding murine PSCA (DCLV-PSCA) as a novel tumor vaccine for prostate cancer in mouse models.

97 vity of an autologous GM-CSF gene-transduced tumor vaccine for RCC patients.

98 lications for the use of GM-CSF-G250 FP as a tumor vaccine for the treatment of patients with advance

99 tope, thereby enhancing its potential use in tumor vaccines for appropriately selected cancer patient

100 laboratory data stress the vast potential of tumor vaccines for the treatment of cancer.

101 he formation of immune complexes that target tumor vaccines for uptake by APCs, via the interaction o

102 f animals receiving the irradiated wild-type tumor vaccine grew large tumors, and 50% died.

103 or antigens to antigen presenting cells, HSP tumor vaccine has been tested in clinical trials.

104 vectors (PNVs)) as potential carriers for DC tumor vaccines has not been presented before.

105 f the allogeneic environment on responses to tumor vaccines has not been well characterized.

106 omising new therapeutic approaches including tumor vaccine have been explored.

107 Historically poor clinical results of tumor vaccines have been attributed to weakly immunogeni

108 olony-stimulating factor (GM-CSF) -secreting tumor vaccines have demonstrated bioactivity but may be

109 Dendritic cell (DC)-based tumor vaccines have only achieved limited clinical effic

110 Tumor vaccines have shown promise in early clinical tria

111 e immune responses and limit the efficacy of tumor vaccines; however, it remains a challenge to selec

112 effective than other modes of creating whole tumor vaccines, i.e., UV or ionizing irradiation, and un

113 summarizes the use of adoptive cell therapy, tumor vaccines, immune checkpoint inhibitors, and combin

114 of delayed-type hypersensitivity to a model tumor vaccine in mice and enhanced the Ag-presenting fun

115 e to the use of the in vivo HSP/suicide gene tumor vaccine in therapy for human solid tumors.

116 ll function in vitro and in the context of a tumor vaccine in vivo.

117 We have developed a tumor vaccine in which patient-derived myeloma cells are

118 mor immunity has reshaped the development of tumor vaccines in clinical medicine.

119 ggested that the immunogenicity of autologus tumor vaccines in humans may be augmented by engineering

120 major implications for the implementation of tumor vaccines in humans.

121 ng doses of chemotherapy in combination with tumor vaccines in patients with cancer.

122 DC-based or protein-based tumor vaccines, in combination with B7-H1 blockade, indu

123 to turn a patient's tumor into an endogenous tumor vaccine; in this context of RF ablation-triggered

124 factor (GM-CSF) gene-transduced, irradiated tumor vaccines induce potent, T-cell-mediated antitumor

125 ive radiation therapy to generate an in situ tumor vaccine, induce CD8+ T cells against tumor-associa

126 n IL-12-transduced but not a mock-transduced tumor vaccine induces systemic tumor immunity in anti-CD

127 ogical endpoints in early clinical trials of tumor vaccines, investigate the design implications of a

128 , as such, has served as the major model for tumor vaccine investigation in both the laboratory and t

129 ses after the administration of three potent tumor vaccines: irradiated MCA 105, MCA 105 admixed with

130 y of tumor-associated antigens in autologous tumor vaccines is limited because of insufficient uptake

131 The therapeutic activity of tumor vaccines is limited by the sheer physical burden o

132 A major prerequisite for the success of tumor vaccines is their effective uptake by antigen-pres

133 acilitating effective Ag presentation by the tumor vaccine itself.

134 hat immunization of BMT donors with cellular tumor vaccines leads to curative GVT but induces unaccep

135 icate that genetically engineered autologous tumor vaccines may be capable of inducing significant an

136 ulocyte-macrophage colony-stimulating factor tumor vaccines may generate a diverse repertoire of tumo

137 mmune responses, this HSP-mediated oncolytic tumor vaccine might become a universally applicable, per

138 f helper epitopes from foreign antigens into tumor vaccines might enhance the immunogenicity of DNA v

139 In a therapeutic tumor vaccine model, immunization with the melanoma pept

140 ection from tumor engraftment in a syngeneic tumor vaccine model, inhibited neutrophil extravasation,

141 n situ, to quantify APC delivery to LNs in a tumor vaccine model.

142 In tumor vaccine models, drugs that induce cell surface cal

143 ression, Sp17 may be an excellent target for tumor vaccine of MM.

144 Tumor vaccines offer the potential for preventing cancer

145 -cell activity might improve the efficacy of tumor vaccines or the immunotherapy of cancer.

146 Cellular therapies outperformed tumor vaccines (OS as HR: P = .005, month difference: P

147 murine models, transgenic chemokine-cytokine tumor vaccines overcome many of the limitations of singl

148 mmunization of donors with recipient-derived tumor vaccines preferentially induces tumor-specific T-c

149 ith autologous, GM-CSF-secreting, irradiated tumor vaccines prepared from ex vivo retroviral transduc

150 Tumor vaccines produced using HSV amplicon-mediated gene

151 oluble Flt3-L, administration of Flt3-L as a tumor vaccine protected mice from a subsequent challenge

152 therefore have implications in the APC-based tumor vaccine protocol design.

153 we developed a novel HSP-mediated oncolytic tumor vaccine, referred to as HOT vaccine, by combining

154 e of their having sufficient immunogenicity, tumor vaccines remain largely ineffective.

155 intensive effort, the antitumor efficacy of tumor vaccines remains limited in treating established t

156 Tumor vaccines represent a promising therapeutic approac

157 DC-based tumor vaccine research has largely focused on enhancing

158 reased 1.9-fold and 16.4-fold by Flt3L or DC tumor vaccines, respectively.

159 These results suggest that whereas B7-1+ tumor vaccines result in some degree of direct presentat

160 sentation is difficult to achieve by current tumor vaccine strategies.

161 a suitable disease for genetically modified tumor vaccine strategies.

162 e have developed a molecular chaperone-based tumor vaccine that reverses the immune tolerance of canc

163 unization of cancer patients with autologous tumor vaccines that are engineered to express alpha-gal

164 Reports of novel developments in tumor vaccines that have appeared in the year ending May

165 One way to improve current tumor vaccines that mainly induce CTLs would be to activ

166 ld be useful for the development of DC-based tumor vaccine therapies.

167 rovide the foundation for the development of tumor vaccines through the use of cytotoxic T cells to i

168 was to examine whether DKK1 can be used as a tumor vaccine to elicit DKK1-specific immunity that can

169 ulfilling this requirement should be used as tumor vaccines, together with DC maturating agents, espe

170 s-priming of therapeutic CD8(+) T cells by a tumor vaccine transduced with GM-CSF requires TNFR, IL-1

171 survived, while all nontreated controls and tumor vaccine-treated rats died within 40 days.

172 of sulfhydryl groups may also occur in vivo, tumor vaccines using this or other cysteine-containing p

173 ytotoxic chemotherapy can be integrated with tumor vaccines using unique doses and schedules to break

174 In this study, the efficacy of 3H1 as a tumor vaccine was evaluated in a murine tumor model.

175 t with the in vitro data, only DC/irradiated tumor vaccines were effective in preventing or delaying

176 Tumor vaccines were produced by brief (20 minutes) expos

177 destruction in situ may provide a polyvalent tumor vaccine without a requirement for knowledge of the

178 d B16 vaccines enhanced clinical activity of tumor vaccines without exacerbating GVHD.

179 ines up to the feasible limits of autologous tumor vaccine yield.